Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;187(6):1022-1024.
doi: 10.1111/bjd.21794. Epub 2022 Sep 6.

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Affiliations

Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Dora Stölzl et al. Br J Dermatol. 2022 Dec.

Abstract

This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.

PubMed Disclaimer

References

    1. Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.
    1. Ratchataswan T, Banzon TM, Thyssen JP et al. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract 2021; 9:1053-65.
    1. Stölzl D, Weidinger S, Drerup K. A new era has begun: treatment of atopic dermatitis with biologics. Allergol Select 2021; 5:265-73.
    1. Drucker AM, Morra DE, Prieto-Merino D et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 2022; 158:523-32.
    1. Schmitt J, Abraham S, Trautmann F et al. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany. J Dtsch Dermatol Ges 2017; 15:49-59.

Substances